High Exploratory Phenotype Rats Exposed to Environmental Stressors Present Memory Deficits Accompanied by Immune-Inflammatory/Oxidative Alterations: Relevance to the Relationship Between Temperament and Mood Disorders.
animal model
bipolar disorder
memory impairment
neuroinflammation
paradoxical sleep deprivation
temperament
unpredictable stress
Journal
Frontiers in psychiatry
ISSN: 1664-0640
Titre abrégé: Front Psychiatry
Pays: Switzerland
ID NLM: 101545006
Informations de publication
Date de publication:
2019
2019
Historique:
received:
08
04
2019
accepted:
15
07
2019
entrez:
21
8
2019
pubmed:
21
8
2019
medline:
21
8
2019
Statut:
epublish
Résumé
Low-exploratory (LE) and high-exploratory (HE) rodents mimic human depressive and hyperthymic temperaments, respectively. Mood disorders (MD) may be developed by the exposure of these temperaments to environmental stress (ES). Psychiatric symptoms severity in MD patients is related to the magnitude of memory impairment. Thus, we aimed at studying the consequences of the exposure of LE and HE male Wistar rats, during periadolescence, to a combination of ES, namely, paradoxical sleep deprivation (PSD) and unpredictable stress (US), on anxiety-related behavior in the plus maze test, working (WM) and declarative memory (DM) performance. We also evaluated hippocampal immune-inflammatory/oxidative, as consequences of ES, and prevention of ES-induced alterations by the mood-stabilizing drugs, lithium and valproate. Medium exploratory (ME) control rats were used for comparisons with HE- and LE-control rats. We observed that HE-controls presented increased anxiolytic behavior that was significantly increased by ES exposure, whereas LE-controls presented increased anxiety-like behavior relative to ME-controls. Lithium and valproate prevented anxiolytic alterations in HE+ES rats. HE+ES- and LE+ES-rats presented WM and DM deficits. Valproate and lithium prevented WM deficits in LE-PSD+US rats. Lithium prevented DM impairment in HE+ES-rats. Hippocampal levels of reduced glutathione (GSH) increased four-fold in HE+ES-rats, being prevented by valproate and lithium. All groups of LE+ES-rats presented increased levels of GSH in relation to controls. Increments in lipid peroxidation in LE+ES- and HE+ES-rats were prevented by valproate in HE+ES-rats and by both drugs in LE+ES-rats. Nitrite levels were increased in HE+ES- and LE+ES-rats (five-fold increase), which was prevented by both drugs in LE+ES-rats. HE+ES-rats presented a two-fold increase in the inducible nitric oxide synthase (iNOS) expression that was prevented by lithium. HE+ES-rats showed increased hippocampal and plasma levels of interleukin (IL)-1β and IL-4. Indoleamine 2, 3-dioxygenase 1 (IDO1) was increased in HE+ES- and LE+ES-rats, while tryptophan 2,3-dioxygenase (TDO2) was increased only in HE+ES-rats. Altogether, our results showed that LE- and HE-rats exposed to ES present distinct anxiety-related behavior and similar memory deficits. Furthermore, HE+ES-rats presented more brain and plasma inflammatory alterations that were partially prevented by the mood-stabilizing drugs. These alterations in HE+ES-rats may possibly be related to the development of mood symptoms.
Identifiants
pubmed: 31428001
doi: 10.3389/fpsyt.2019.00547
pmc: PMC6689823
doi:
Types de publication
Journal Article
Langues
eng
Pagination
547Références
Neuroscience. 1999;93(1):243-51
pubmed: 10430488
Physiol Behav. 1999 Nov;67(5):643-9
pubmed: 10604833
Neurosci Biobehav Rev. 2000 Jun;24(4):417-63
pubmed: 10817843
J Neurochem. 2001 Feb;76(3):846-54
pubmed: 11158256
J Neurosci. 2001 Sep 1;21(17):6480-91
pubmed: 11517237
ILAR J. 1997;38(1):41-48
pubmed: 11528046
J Neurosci. 2003 Aug 13;23(19):7311-6
pubmed: 12917364
Sleep. 2004 Feb 1;27(1):27-35
pubmed: 14998234
Neuropharmacology. 2004 May;46(6):895-903
pubmed: 15033349
Brain Res. 2004 Apr 9;1004(1-2):45-51
pubmed: 15033418
J Affect Disord. 2004 Oct 1;82(1):131-4
pubmed: 15465586
Dev Psychobiol. 2004 Nov;45(3):153-62
pubmed: 15505797
Prog Neuropsychopharmacol Biol Psychiatry. 1992 Jan;16(1):117-25
pubmed: 1557503
Neurosci Biobehav Rev. 2005 Feb;29(1):99-112
pubmed: 15652258
Sleep. 2005 Jan;28(1):55-67
pubmed: 15700721
Learn Mem. 2005 May-Jun;12(3):352-9
pubmed: 15897251
Behav Brain Res. 2005 Jul 30;162(2):272-8
pubmed: 15970221
Biol Psychiatry. 2005 Dec 1;58(11):879-84
pubmed: 16005436
Life Sci. 2006 May 8;78(24):2833-8
pubmed: 16325867
Psychopharmacology (Berl). 2006 Jan;184(1):1-12
pubmed: 16341847
Neuroimage. 2006 May 15;31(1):419-28
pubmed: 16427321
Pharmacol Biochem Behav. 2006 Feb;83(2):186-93
pubmed: 16519925
Behav Brain Funct. 2006 Mar 28;2:10
pubmed: 16569223
Trends Neurosci. 2006 Sep;29(9):496-505
pubmed: 16872686
Exp Neurol. 2007 Jan;203(1):241-5
pubmed: 17007839
Behav Brain Res. 2007 Feb 27;177(2):269-81
pubmed: 17141886
Brain Res. 2007 Feb 2;1131(1):138-48
pubmed: 17156751
Biogerontology. 2008 Jun;9(3):153-62
pubmed: 18224455
Am J Med Genet B Neuropsychiatr Genet. 2008 Mar 5;147B(2):134-66
pubmed: 18247375
PLoS Med. 2008 Apr 1;5(4):e61
pubmed: 18384228
Neurobiol Learn Mem. 2008 Nov;90(4):624-32
pubmed: 18707010
Dev Psychopathol. 2009 Winter;21(1):47-68
pubmed: 19144222
Synapse. 2009 May;63(5):443-6
pubmed: 19184998
J Neurosci. 2009 Apr 1;29(13):4200-9
pubmed: 19339614
Behav Brain Res. 2010 Mar 5;207(2):305-9
pubmed: 19850085
Front Neuroendocrinol. 2010 Apr;31(2):232-40
pubmed: 20193707
Sleep. 2010 Dec;33(12):1669-79
pubmed: 21120129
J Leukoc Biol. 2011 Jun;89(6):873-91
pubmed: 21233414
Transl Res. 2011 Feb;157(2):100-7
pubmed: 21256462
Neurosci Res. 2011 May;70(1):71-7
pubmed: 21256900
Behav Brain Res. 2011 Jun 20;220(1):106-11
pubmed: 21277333
J Psychopharmacol. 2011 Jul;25(7):934-43
pubmed: 21421642
Neurosci Lett. 2011 Jul 15;499(1):28-31
pubmed: 21624432
J Endocrinol. 2011 Sep;210(3):391-8
pubmed: 21746793
J Abnorm Psychol. 2012 Feb;121(1):39-50
pubmed: 21842957
Eur J Neurosci. 2011 Sep;34(6):1023-30
pubmed: 21884554
Prog Neuropsychopharmacol Biol Psychiatry. 2012 Aug 7;38(2):216-22
pubmed: 22521334
Behav Brain Res. 2012 Jul 15;233(1):62-70
pubmed: 22565029
Compr Psychiatry. 2012 Nov;53(8):1096-102
pubmed: 22727729
Bipolar Disord. 2012 Nov;14(7):707-18
pubmed: 22897629
J Neuroimmunol. 2013 Jan 15;254(1-2):1-9
pubmed: 23021418
Brain Res. 2012 Dec 7;1488:38-50
pubmed: 23099054
Prog Neuropsychopharmacol Biol Psychiatry. 2013 Jun 3;43:230-7
pubmed: 23333378
Science. 2013 Mar 1;339(6123):1095-9
pubmed: 23449593
Cell Commun Signal. 2013 May 17;11(1):34
pubmed: 23683503
Clinics (Sao Paulo). 2013 Apr;68(4):449-55
pubmed: 23778335
Naunyn Schmiedebergs Arch Pharmacol. 2014 Feb;387(2):129-41
pubmed: 24132508
Sleep. 2013 Nov 01;36(11):1677-84
pubmed: 24179301
Braz J Psychiatry. 2013;35 Suppl 2:S121-31
pubmed: 24271224
Curr Pharm Des. 2014;20(31):5104-14
pubmed: 24345269
J Pharmacol Exp Ther. 2014 Jun;349(3):497-507
pubmed: 24706984
Neurosci Biobehav Rev. 2014 Sep;45:46-62
pubmed: 24858007
J Affect Disord. 2014 Aug;165:131-4
pubmed: 24882190
Sleep. 2014 Nov 01;37(11):1799-807
pubmed: 25364075
Stress. 2015 Jan;18(1):96-106
pubmed: 25472821
Biostat Bioinforma Biomath. 2013 Aug;3(3):71-85
pubmed: 25558171
Front Psychiatry. 2015 Feb 02;6:6
pubmed: 25698978
Neurochem Res. 2015 Jun;40(6):1144-52
pubmed: 25894682
Oxid Med Cell Longev. 2015;2015:234952
pubmed: 25945148
Neuroscience. 2015 Aug 6;300:141-54
pubmed: 25981208
J Affect Disord. 2015 Sep 15;184:51-9
pubmed: 26070046
Neural Plast. 2015;2015:692541
pubmed: 26075103
Glia. 2015 Dec;63(12):2274-84
pubmed: 26184677
J Neurosci. 2015 Aug 12;35(32):11281-91
pubmed: 26269636
J Neurodegener Dis. 2015;2015:313702
pubmed: 26317011
Neuroreport. 2015 Dec 16;26(18):1145-50
pubmed: 26512932
PLoS One. 2015 Nov 18;10(11):e0141908
pubmed: 26580066
J Ethnopharmacol. 2016 Dec 24;194:819-826
pubmed: 27623554
J Neurosci. 2016 Oct 26;36(43):10990-11005
pubmed: 27798180
Sleep Med. 2016 Aug;24:71-79
pubmed: 27810189
Front Neurol. 2016 Nov 02;7:189
pubmed: 27853449
Behav Brain Res. 2017 Mar 15;321:69-78
pubmed: 28043900
Psychopharmacology (Berl). 1988;94(4):491-5
pubmed: 2836875
Bipolar Disord. 2017 Jun;19(4):246-258
pubmed: 28612976
J Neurosci Methods. 1985 Aug;14(3):149-67
pubmed: 2864480
J Neuroimmunol. 2017 Nov 15;312:38-48
pubmed: 28912034
Stress. 2017 Nov;20(6):598-607
pubmed: 29020870
Psychiatry Res. 2018 Aug;266:328-333
pubmed: 29588062
Int J Environ Res Public Health. 2018 May 28;15(6):
pubmed: 29843433
Neurotox Res. 2019 Jan;35(1):122-138
pubmed: 30056534
Front Psychol. 2018 Aug 29;9:1625
pubmed: 30210421
J Nutr Biochem. 2019 Feb;64:61-71
pubmed: 30445417
Neurosci Res. 2019 Jan 24;:null
pubmed: 30685492
Int J Physiol Pathophysiol Pharmacol. 2018 Dec 25;10(6):184-191
pubmed: 30697365
Braz J Psychiatry. 2019 Jul-Aug;41(4):289-296
pubmed: 30892378
Oxid Med Cell Longev. 2019 Feb 17;2019:8745376
pubmed: 30911352
Arch Gen Psychiatry. 1987 Jun;44(6):573-88
pubmed: 3579504
Anal Biochem. 1968 Oct 24;25(1):192-205
pubmed: 4973948
Anal Biochem. 1978 May;86(1):271-8
pubmed: 655387
Pharmacol Biochem Behav. 1982 Dec;17(6):1119-22
pubmed: 7163344
J Interferon Cytokine Res. 1995 Jul;15(7):617-24
pubmed: 7553232
Adv Biochem Psychopharmacol. 1995;49:99-112
pubmed: 7653337
Physiol Behav. 1994 Oct;56(4):775-9
pubmed: 7800747
Arch Gen Psychiatry. 1993 Dec;50(12):975-90
pubmed: 8250684
Eur Neuropsychopharmacol. 1995;5 Suppl:89-93
pubmed: 8775765
Eur Neuropsychopharmacol. 1995 Dec;5(4):447-55
pubmed: 8998396
Physiol Behav. 1997 Feb;61(2):249-56
pubmed: 9035255
Prog Neurobiol. 1998 Jan;54(1):99-125
pubmed: 9460796
Neurobiol Learn Mem. 1998 Mar;69(2):211-7
pubmed: 9619997
J Affect Disord. 1998 Oct;51(1):21-32
pubmed: 9879800